Scandion Oncology A/S today announced that the company has obtained approval from the German regulatory authorities to initiate clinical trials in Germany with SCO-101 in the PANTAX Ib study.
The German medicines agency (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the German ethics committee have given approval, allowing Scandion Oncology to expand the PANTAX Ib study to Germany.
“We are very pleased to receive this German approval as BfArM is highly regarded and known for having tough critera. The approval is important for the PANTAX Ib study, but it also opens the door to starting trials in Germany with SCO-101 in other indications. We will communicate more about our plans and strategy at our Capital Markets Day on September 8,” said Bo Rode Hansen, President & CEO of Scandion Oncology.
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
The information was provided by the contact person above for publication on August 27, 2021.
Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.